`
`
`
`Technical R&D / BPRD
`
`0.5MG/0.05ML Liquid in (pre-filled) syringe
`
`Development Report
`
`Author(s):
`
`Valid date:
`
`Sigg Jurgen
`
`Date of approval
`
`Numberof pages:
`
`117
`
`Property of Novartis
`Confidential
`May not be used, divulged, published or otherwise disclosed
`without the consent of Novartis
`
`
`| BESei
`ar ub. Maro. <Vis TAs Ont
`
`S42GFR in dachase TEM CH} hac heen dinitally ciceecd wit
`24> 3G:
`CUS S€
`2
`SIRS Wi
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`
`NOVITC(CH)00167663
`
`Novartis Exhibit 2128.001
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`